Many of us know that Asia has a high prevalence of MMD for unknown reasons. The numbers are staggering with up to 80% of all people-- specifically in China and Singapore. The prevalence of severe myopia too, is skyrocketing.

I believe that ACT is determined to tap into this market. My guess is not China(we could go on all day about why that would be), but instead Singapore!!

Of course, we put together many threads after Lanza made a keynote speech at the 4th annual stem

Read More

So satisfying to hear Gary withdraw ACT from the conventional cell therapy approaches. NO, this company is not comparable to any of the names you have mentioned, and we are targeting indications that are on a much larger scale. ACT stands alone and Gary has made that very clear.



This strategic plan is a big deal. Obviously augmenting the management team of the company with plans to commercialize these projects was one of the components of this plan. Getting on the NASDAQ,

Read More

Gary did a really great job recently in his attempt to identify the differentiating factors that encompass ACT. At what point, however, does this "Event-Driven" company define its long-term strategic planning?

In saying that, I mean at what point does ACT grow a spine and produce a trade name for MA-09RPE?

at what point, does Gary introduce ACT's strategic planning--for more than one year at a time?

Common questions a company must ask itself:

1. "What

Read More

This was going to be a post but got way too off topic and started to get personal, so I'll just blog it?


horrible conference if you ask me. most of what i heard i either found annoying or frustrating. I can't believe all these scientists can be so polarized. I can feel the frustration in Vincent's tone by the end, Rabin was rushing throughout the entire presentation...and Im not sure that a lot of people were able to grasp the differences from a manufacturing, efficacy/potency,

Read More

These are the two posts I probably spent the most time on, and to this day, they represent my sentiment in ACT, Lanza, and Biocentrism moving forward.



However futile, I want to analyze our mixed determination along with the philosophical appeal toward ACT. I offer a few propositions that have protected my positive outlook during this stretch of irresolution. Sympathizing to the longs, I settle on the notion that as a result of the underlining conformant factors, some of

Read More